Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Key Points The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant pre-market approval for Galleri following this week's vote. 10 stocks we like better than Grail › Grail 's (NASDAQ: GRAL) stock surged after a Food and Drug Administration (FDA) Advisory Committee voted favorably on the safety, benefit-risk profile, and effectiveness of its multi-cancer early detection test (MCED), Galleri. It marks a remarkable turnaround for the stock after a February crash following the release of top-line results from a landmark Galleri trial that revealed it had missed its primary endpoint. Here's why this recovery could continue. The investment case for Grail stock The Galleri test is already in use.